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Why dedicated venous stents?
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Expectations 
Precise deployment
Less foreshortening
Flexibility
Optimal accommodation to venous anatomy
Equally distributed radial force
Throughout stent length
Wall coverage
Protecting stent lumen from fibrotic tissue
Durability
At critical sites
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Prospective, on-going register including patients who received venous 
stents in Switzerland since 2011
From 274 patients in the registry, 62 patients received caval or ilio-caval
stent interventions with nitinol stents (212 excluded with ilio-femoral 
stents only)
Stents used:
Sinus XL, Sinus XL Flex, Sinus Superflex (Optimed, Ettlingen, Germany)
Zilver vena (Cook, Bloomington, USA)
Sebastian T, Dopheide JF, Engelberger RP, Spirk D, Kucher N.
Outcomes of endovascular reconstruction of the inferior vena cava with self-expanding nitinol stents.
J Vasc Surg Venous Lymphat Disord. 2018 (in-press)
Swiss Venous Stent Registry
Baseline characteristics
Mean age 46 ± 18 years, 14 women
Index Diagnosis
33 post-thrombotic syndrome (53%)
17 acute thrombosis (27%)
12 non-thrombotic IVC compression (19%)
22 external IVC compression
16 cancer related, 3 retroperitoneal fibrosis, 1 echinococcosis, 1 
abdominal aortic aneurysm, 1 vertebral screws
Sebastian T, Dopheide JF, Engelberger RP, Spirk D, Kucher N.
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J Vasc Surg Venous Lymphat Disord. 2018 (in-press)
Procedural data
Technical success 61 (98%)
CDT or PMT 21 (34%)
Iliac kissing stents 52 (84%)
IVC Filters 0
Mean number of stents 4.5 ± 1.9 stents
Mean stent length 45 ± 20 cm
Proximal landing zone 
Right atrium 7 (11%) Suprarenal 42 (68%) Infrarenal 13 (21%)
Sebastian T, Dopheide JF, Engelberger RP, Spirk D, Kucher N.
Outcomes of endovascular reconstruction of the inferior vena cava with self-expanding nitinol stents.
J Vasc Surg Venous Lymphat Disord. 2018 (in-press)
Procedural data
Type I: Single-segment stenosis: 4 (6%)
Type II: Multi-segment stenosis: 14 (23%)
Type III: Singe-segment occlusion: 2 (3%)
Type IV: Multi-segment occlusion: 42 (68%)
Sebastian T, Dopheide JF, Engelberger RP, Spirk D, Kucher N.
Outcomes of endovascular reconstruction of the inferior vena cava with self-expanding nitinol stents.
J Vasc Surg Venous Lymphat Disord. 2018 (in-press)

Patency Outcome
Mean follow up 21 months, death 4 (underlying malignant disease)
Symptomatic stent occlusion: 13 (21%)
Symptomatic stent stenosis: 10 (16%)
Re-intervention: 22 (36%)
Permanent loss of patency: 5 (8%)
Sebastian T, Dopheide JF, Engelberger RP, Spirk D, Kucher N.
Outcomes of endovascular reconstruction of the inferior vena cava with self-expanding nitinol stents.
J Vasc Surg Venous Lymphat Disord. 2018 (in-press)
Clinical Outcome
Ulcer healing: 8/8 (100%)
Development of new ulcers: 0%
Freedom of symptoms1: 43%
Significant clinical improvement1: 48%
1: subjective symptom score as suggested by Bozkaya et al.
Decrease in Villalta score: 11.8 to 3.5
Sebastian T, Dopheide JF, Engelberger RP, Spirk D, Kucher N.
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Clinical Outcome
On-going anticoagulation therapy 56 (92%) patients
DOACs 40 (66%) patients
Vitamin K antagonists 14 (23%) patients
LMWH 2 (3%) patients
+ P2Y12 antagonists 7 (11%) patients
Sebastian T, Dopheide JF, Engelberger RP, Spirk D, Kucher N.
Outcomes of endovascular reconstruction of the inferior vena cava with self-expanding nitinol stents.
J Vasc Surg Venous Lymphat Disord. 2018 (in-press)
Predictors of patency loss
Patients with a history of deep vein thrombosis and/or posthrombotic
leg inflow veins are at high risk for primary patency loss.
Stenting below the inguinal ligament was not associated with loss of 
primary patency in our cohort.
Sebastian T, Dopheide JF, Engelberger RP, Spirk D, Kucher N.
Outcomes of endovascular reconstruction of the inferior vena cava with self-expanding nitinol stents.
J Vasc Surg Venous Lymphat Disord. 2018 (in-press)
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What’s in the literature
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Follow Up
(months)
Acute
Cases
Technical 
Success
Main 
Stent
Primary 
Patency
Secondary 
Patency
Ulcer
Healing
Anti-
coagulation
De Graaf
2015
40 15 15% 100% Nitinol 70% 78% N/A VKA (min 6m)
Murphy 
2016
71 48 0% 85%
Wallstent
Z-Stent
52% 93% 78%
VKA 
ASS (life)
Chick
2017
120 24 48% 100% Wallstent 87% 94% 88%
VKA/DOAC (min 
6m) Clop (2m) 
ASS (life)
Erben
2018
66 42 2% 90%
Wallstent
Z-Stent
78% 91% 100% OAC (life)
Sebastian 
2018
62 21 27% 98% Nitinol 57% 87% 100%
VKA /
DOACs
(life)
Selection of recent publications on ilio-caval stent reconstuction
IVC filter-associated: Murphy (54%), Chick (100%), Erben (38%) 
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Conclusion
Primary patency rate beyond 2 years for nitinol stents is  >55%
Secondary interventions are often necessary to maintain patency, most likely 
due to impaired venous stent inflow 
Secondary patency rates can be as high as 90%
Role of anticoagulation / anti-platelet therapy is unclear
Data for nitinol stents is similar compared to Wallstents
Thank you for your attention.
